KNTE
Price:
$2.65
Market Cap:
$124.99M
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinna...[Read more]
Industry
Biotechnology
IPO Date
2020-12-03
Stock Exchange
NASDAQ
Ticker
KNTE
According to Kinnate Biopharma Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 71.17M. This represents a change of -28.88% compared to the average of 100.07M of the last 4 quarters.
The mean historical Enterprise Value of Kinnate Biopharma Inc. over the last ten years is 725.01M. The current 71.17M Enterprise Value has changed 881.62% with respect to the historical average. Over the past ten years (40 quarters), KNTE's Enterprise Value was at its highest in in the December 2019 quarter at 1.62B. The Enterprise Value was at its lowest in in the March 2020 quarter at 0.
Average
725.01M
Median
535.54M
Minimum
56.56M
Maximum
1.61B
Discovering the peaks and valleys of Kinnate Biopharma Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 289.48%
Maximum Annual Enterprise Value = 1.61B
Minimum Annual Increase = -76.79%
Minimum Annual Enterprise Value = 56.56M
Year | Enterprise Value | Change |
---|---|---|
2023 | 56.56M | -76.79% |
2022 | 243.72M | -62.88% |
2021 | 656.52M | -51.87% |
2020 | 1.36B | -15.52% |
2019 | 1.61B | 289.48% |
The current Enterprise Value of Kinnate Biopharma Inc. (KNTE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
318.93M
5-year avg
787.10M
10-year avg
725.01M
Kinnate Biopharma Inc.’s Enterprise Value is less than Ambrx Biopharma Inc. (1.56B), less than Acelyrin, Inc. (296.05M), greater than Windtree Therapeutics, Inc. (3.72M), greater than Palisade Bio, Inc. (-6597681.00), less than Century Therapeutics, Inc. (138.60M), greater than Passage Bio, Inc. (44.87M), greater than Homology Medicines, Inc. (-103303255.00), less than Generation Bio Co. (210.95M), less than Stoke Therapeutics, Inc. (586.20M), less than Gracell Biotechnologies Inc. (5.45B), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (284.72M), less than Design Therapeutics, Inc. (221.42M), less than Erasca, Inc. (689.13M), greater than Kronos Bio, Inc. (16.29M), less than C4 Therapeutics, Inc. (369.73M), less than Edgewise Therapeutics, Inc. (1.60B), greater than Surrozen, Inc. (-6000669.00), greater than Bolt Biotherapeutics, Inc. (37.47M), less than Larimar Therapeutics, Inc. (486.93M), less than Keros Therapeutics, Inc. (1.58B), greater than Kezar Life Sciences, Inc. (30.16M),
Company | Enterprise Value | Market cap |
---|---|---|
1.56B | $1.77B | |
296.05M | $423.19M | |
3.72M | $1.66M | |
-6597681.00 | $4.25M | |
138.60M | $123.69M | |
44.87M | $43.48M | |
-103303255.00 | $3.02M | |
210.95M | $145.50M | |
586.20M | $773.92M | |
5.45B | $989.87M | |
138.26M | $181.50M | |
284.72M | $349.21M | |
221.42M | $264.42M | |
689.13M | $807.96M | |
16.29M | $59.36M | |
369.73M | $374.42M | |
1.60B | $1.64B | |
-6000669.00 | $29.60M | |
37.47M | $24.78M | |
486.93M | $513.64M | |
1.58B | $1.97B | |
30.16M | $40.82M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kinnate Biopharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kinnate Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Kinnate Biopharma Inc.'s Enterprise Value?
What is the highest Enterprise Value for Kinnate Biopharma Inc. (KNTE)?
What is the 3-year average Enterprise Value for Kinnate Biopharma Inc. (KNTE)?
What is the 5-year average Enterprise Value for Kinnate Biopharma Inc. (KNTE)?
How does the current Enterprise Value for Kinnate Biopharma Inc. (KNTE) compare to its historical average?